[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-361536-105":59,"doc-detail-361536-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-chrono-trial-protocol-early-time-restricted-eating","The CHRONO trial - Protocol - early time-restricted eating","","Fasting combined with anti-cancer therapies improves tumor regression and survival in animals. This protocol describes a single-blind, randomized controlled trial testing whether time-restricted eating (TRE) improves clinical, molecular, and behavioral outcomes in patients with breast or rectal cancer. The study will enroll 175 adults with newly diagnosed stage I-III HER2-positive or triple-negative breast cancer or stage II-IV rectal cancer receiving neoadjuvant therapy, with participants randomized to early TRE versus a ≥12-hour eating window.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-chrono-trial-protocol-early-time-restricted-eating/361536/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-chrono-trial-protocol-early-time-restricted-eating/361536.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What treatment strategy does the CHRONO trial evaluate?","Question",{"text":112,"@type":113},"The trial tests time-restricted eating (TRE), comparing early time-restricted eating (eTRE; ≤8-hour eating window early in the day) with an eating window of ≥12 hours.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who will be enrolled in the study?",{"text":117,"@type":113},"The trial will enroll 175 adults with newly diagnosed stage I-III HER2-positive or triple-negative breast cancer or stage II-IV rectal cancer receiving neoadjuvant therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the primary and secondary outcomes?",{"text":121,"@type":113},"Primary outcomes are the pathologic complete response, organ preservation rate, and patient-reported adverse events. Secondary outcomes include clinical and tumor response, quality of life, and provider-reported adverse events.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},361536,1791116193,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Nutr Res. Author manuscript; available in PMC 2026 September 16. |\n| --- | --- |\n\nPublished in final edited form as:  \nNutr Res. 2026 July ; 151: 77–94. doi:10.1016/j.nutres.2026.04.016 .  \nThe CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer ☆  \nSarah-Jeanne Salvya,* , Jane C. Figueiredoa, Katelyn M. Atkinsb, Robert H. Hollisc, Nusrat Jahand, Drew J. Gunnellsc, Alix G. Sleighte, Gillian Greshama, Márcio A. Dinizf, Joshua S. Richmang, Jun Gonga, Karen Zaghiyanh, Martin J. Heslinc, Kevin J. Leei, Humaira Sarfrazd, Courtney M. Petersonj  \na Department of Medicine, Samuel Oschin Comprehensive Cancer Center Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA  \nb Department of Radiation Oncology, Samuel Oschin Comprehensive Cancer Center Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA  \nc Division of Gastrointestinal Surgery, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA  \nd Division of Hematology and Oncology, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA  \neChan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA, USA  \nfDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA  \ng Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA  \n☆Institutional Review Board Statement: The study is being conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Boards of Cedars-Sinai Medical Center (STUDY00001187; April 8, 2021) and the University of Alabama at Birmingham (IRB-300007335; August 2, 2021). The study is [registered on](registered on ClinicalTrials.gov)[ ClinicalTrials.gov](registered on ClinicalTrials.gov) (NCT04722341).  \nThis is an open access article under the CC BY-NC license ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/))  \n*Corresponding author at: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, 250 N Robertson Blvd., Suite 502, Beverly Hills, [CA 90211. sarah.salvy@cshs.org](CA 90211. sarah.salvy@cshs.org) (S.-J. Salvy).  \nDeclaration of generative AI and AI-assisted technologies in the writing process No AI or AI-assisted technologies were used during the preparation of this work.  \nAuthor declarations None.  \nCRediT authorship contribution statement  \nSarah-Jeanne Salvy: Writing – review & editing, Writing – original draft, Supervision, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization. Jane C. Figueiredo: Funding acquisition, Conceptualization. Katelyn M. Atkins: Investigation, Data curation. Robert H. Hollis: Writing – review & editing, Resources, Data curation. Nusrat Jahan: Writing – review & editing, Resources, Data curation. Drew J. Gunnells: Writing – review & editing, Investigation, Data curation. Alix G. Sleight: Resources, Data curation. Gillian Gresham: Writing – review & editing, Conceptualization. Márcio A. Diniz: Writing – review & editing, Methodology, Conceptualization. Joshua S. Richman: Writing – review & editing, Methodology, Formal analysis. Jun Gong: Writing – review & editing, Resources, Investigation, Data curation. Karen Zaghiyan: Writing – review & editing, Resources. Martin J. Heslin: Writing – review & editing, Resources, Data curation. Kevin J. Lee: Data curation. Humaira Sarfraz:  \nWriting – original draft, Resources. Courtney M. Peterson: Writing – review & editing, Writing – original draft, Supervision, Project administration, Methodology, Investigation, Funding acquisition, Conceptualization.  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr","cbCaibTREosrAalA","https://ap.wps.com/l/cbCaibTREosrAalA","pdf",708949,34,"English","# Abstract\n## Trial design and aims\n## Participants and interventions\n## Outcomes and measurements","[{\"question\":\"What treatment strategy does the CHRONO trial evaluate?\",\"answer\":\"The trial tests time-restricted eating (TRE), comparing early time-restricted eating (eTRE; ≤8-hour eating window early in the day) with an eating window of ≥12 hours.\"},{\"question\":\"Who will be enrolled in the study?\",\"answer\":\"The trial will enroll 175 adults with newly diagnosed stage I-III HER2-positive or triple-negative breast cancer or stage II-IV rectal cancer receiving neoadjuvant therapy.\"},{\"question\":\"What are the primary and secondary outcomes?\",\"answer\":\"Primary outcomes are the pathologic complete response, organ preservation rate, and patient-reported adverse events. Secondary outcomes include clinical and tumor response, quality of life, and provider-reported adverse events.\"}]","The CHRONO trial - Protocol - early time-restricted eating | PDF",1790144740,86,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/132b9c2f63cfa672a399e9f679087cc9.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2be4267b8d4808567838884665433626.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b50380cec3e1e7a0607b3fe0bce80670.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa55bec8532525372a17812489ef1908.webp",980,1268]